Madrigal Pharmaceuticals, Inc

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company based in Conshohocken, PA, dedicated to developing innovative therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Their primary focus lies in creating treatments for adults with NASH exhibiting moderate to advanced liver fibrosis, with ongoing research in Phase 3 trials for those with compensated cirrhosis.

With the recent FDA accelerated approval of their first therapy, Madrigal Pharmaceuticals is at the forefront of pioneering treatments for NASH/MASH patients. The company's ambitious research endeavors have resulted in groundbreaking advancements, leading to the development of the first FDA-approved medication specifically tailored to address the challenges faced by patients with NASH.

Generated from the website content